What is Prolocor?
Prolocor operates at the intersection of biotechnology and clinical diagnostics, specifically targeting the unmet needs within cardiovascular health. The company's core innovation lies in its ability to assess and manage patient risk through precise diagnostic tools that quantify specific biomarkers on platelets. This approach moves beyond traditional diagnostic paradigms, offering a more individualized assessment of patient health. By empowering physicians with actionable, high-fidelity information, Prolocor aims to reduce the ambiguity often associated with cardiovascular treatment decisions, thereby improving patient outcomes and streamlining clinical workflows in high-stakes medical environments.
How much funding has Prolocor raised?
Prolocor has raised a total of $4.9M across 2 funding rounds:
Angel/Seed
$3.2M
Debt
$1.7M
Angel/Seed (2022): $3.2M with participation from Green Park & Golf Ventures and Labcorp
Debt (2024): $1.7M led by Green Park & Golf Ventures and Labcorp
Key Investors in Prolocor
Green Park & Golf Ventures
A Dallas-based venture capital firm with over 60 years of combined operational and financial experience, specializing in medical-related start-ups and early-stage healthcare innovation.
Labcorp
A global leader in laboratory services providing vital diagnostic information to hospitals, pharmaceutical companies, and physicians to facilitate confident, data-backed clinical decisions.
What's next for Prolocor?
With this recent strategic financing, Prolocor is well-positioned to accelerate its clinical development roadmap and expand its diagnostic footprint. The company is expected to leverage these resources to refine its FcyRIIa quantification platform, potentially moving toward broader commercial integration within hospital systems and diagnostic laboratories. As the healthcare industry continues to shift toward value-based care and precision diagnostics, Prolocor's focus on actionable, data-driven insights will likely serve as a catalyst for future growth. The company remains committed to bridging the gap between complex biological markers and bedside clinical decision-making, setting the stage for a new standard in cardiovascular risk assessment.
See full Prolocor company page
